Renal Cancer - Results from #2240

Radiomics to better characterize small renal masses. January 28, 2021

Establishment of a Risk Signature Based on m6A RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma. January 27, 2021

Potential diagnostic and prognostic value and regulatory relationship of long noncoding RNA CCAT1 and miR-130a-3p in clear cell renal cell carcinoma. January 27, 2021

Body Mass Index in Patients Treated with Cabozantinib for Advanced Renal Cell Carcinoma: A New Prognostic Factor? January 27, 2021

Primary Small Cell Carcinoma of the Kidney: Disease Characteristics and Treatment Outcomes. January 26, 2021

First Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Diagnostic Imaging Product in the United States January 25, 2021

ACE2 abrogates tumor resistance to VEGFR inhibitors suggesting angiotensin-(1-7) as a therapy for clear cell renal cell carcinoma. January 25, 2021

Radical metastasectomy followed by sorafenib versus observation in patients with clear cell renal cell carcinoma: extended follow up of efficacy results from the randomized phase II RESORT trial. January 25, 2021

Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival. January 25, 2021

External validation of the albumin, C-reactive protein and lactate dehydrogenase model in patients with metastatic renal cell carcinoma receiving second-line axitinib therapy in a Japanese multi-center cohort. January 25, 2021

Dana-Farber Research Supports FDA Approval for Combination of Nivolumab and Cabozantinib in Advanced Kidney Cancer January 23, 2021

Cabozantinib Receives U.S. FDA Approval as a First-Line Treatment in Combination with Nivolumab for Advanced Renal Cell Carcinoma January 22, 2021

The prognostic impact of immune-related adverse events in metastatic renal cell carcinoma patients treated with nivolumab: a real-world multi-institutional retrospective study. January 22, 2021

Prognostic role of PHYH for overall survival (OS) in clear cell renal cell carcinoma (ccRCC). January 22, 2021

Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3/E2F1 axis. January 22, 2021

Otoferlin is a prognostic biomarker in patients with clear cell renal cell carcinoma: A systematic expression analysis. January 21, 2021

Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. January 21, 2021

Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma: Final Overall Survival Analysis of the Phase 3 PROTECT Trial. January 21, 2021

CircPVT1 promotes progression in clear cell renal cell carcinoma by sponging miR-145-5p and regulating TBX15 expression. January 20, 2021

Deep learning based prediction of prognosis in nonmetastatic clear cell renal cell carcinoma. January 20, 2021

Page 113 of 457